



ImmuPharma plc

Blockbuster drugs
for niche markets





DISCLAIMER

This presentation contains certain statements that are not historical facts and may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statement made by ImmuPharma PLC (“the Company”) in respect of itself and its subsidiaries (“ImmuPharma”). These factors include, but are not limited to: (i) ImmuPharma’s and/or ImmuPharma’s partners’ ability to successfully complete product research and development, including pre-clinical and clinical studies and commercialisation; (ii) ImmuPharma’s and/or ImmuPharma’s partners’ ability to obtain required governmental approvals, including product and patent approvals, the impact of pharmaceutical industry regulation, the difficulty of predicting FDA and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries; (iii) the acceptance and demand for new pharmaceutical products and ImmuPharma’s ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (iv) ImmuPharma’s and/or ImmuPharma’s partners’ ability to develop and commercialise products before its competitors and the impact of competitive products and pricing, the availability and pricing of ingredients used in the manufacture of products, uncertainties regarding market acceptance of innovative products newly launched, currently being sold or in development. In addition, significant fluctuations in financial results may occur as a result of the timing of milestone payments and the timing of costs and expenses related to the ImmuPharma’s research and development program. Without limiting the generality of the foregoing, no assurance is given as to when the ImmuPharma’s products will be launched or whether that launch will be commercially successful, and words such as “may,” “will,” “to,” “expect,” “plan,” “believe,” “anticipate,” “intend,” “could,” “would,” “estimate,” or “continue” or the negative or other variations thereof or comparable terminology is intended to identify forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties. The Company, its subsidiaries, Directors, Officers, Associates or Advisors shall under no circumstance be liable to investor or any other third party for any lost profits or lost opportunity, indirect, incidental, consequential, special, or punitive damages whatsoever.

Summary

Company first started in Switzerland; Listed on LSE (AIM) 2006.

Lead Drug candidate Lupuzor™, received approval from FDA to start phase III with an SPA, plus, was granted “Fast Track” designation. ImmuPharma regained rights from Cephalon due to their acquisition by Teva, after a major corporate deal brought \$45m as part of \$500m cash milestones, plus royalties. Successful data from Phase I, Phase IIa and Phase IIb trials.

Second potential blockbuster in clinical trials in cancer patients.

Exclusive and contracted relationship with the CNRS, France’s national scientific research institution, enables low cost research; Three additional product candidates in large specialty areas, plus two proprietary technology platforms.

Experienced and commercially focused management (ex GlaxoSmithKline, Roche, Novartis, Bristol-Myers Squibb, UBS, Commerzbank).



1999



2000



2005

Financials

Issued Share Capital: 81 m shares


Market Cap: £78 m

Quoted since Feb 2006

IFRS Accounts; Corporate Governance, Main Market (LSE)
practice

Liquidity: > £1m / month (avg 12 months)

Monthly traded Value – 12 mths



Source: London Stock Exchange

Shareholders

Management (37%)

Gartmore

M&G (9.3%)

Jupiter

ING (4%)

Schroders Life Sciences

Aviva (2.1%)

Quest

Pictet (4%)

Cheviot

Odey Asset Mgmt (2%)


Brewin Dolphin

Rensburg Sheppards

Powe Capital




Current Pipeline



Collaboration with the Centre National de la Recherche Scientifique (CNRS)

Exclusive collaboration with the Centre National de la Recherche Scientifique, the largest fundamental research organization in Europe with a budget of €3.3bn (2008)*.

CNRS provides access to many scientists and physicians.



* Source: CNRS




Lupuzor™

Treatment of Lupus

A novel drug specific for the treatment of Lupus with multi-billion sales potential.

Recently was granted approval by the FDA to enter phase III with an SPA and Fast Track designation.

In discussions with pharma companies for a corporate deal.





Lupus is a chronic inflammatory disease, sometimes fatal, associated with disorders of the immune system.

Current drugs either have serious side effects or have only limited effectiveness.

Most key competitors in development failed (e.g. Cellcept, Rituxan). Benlysta's approval paves the way for Lupuzor.

Niche market, little competition. 1.5m estimated patients in US, Japan, Germany, France, Italy, UK & Spain. Target price per patient \$10,000 - \$20,000 per year (Benlysta to be priced c. \$35,000).

Lupuzor™ : Development

ImmuPharma's activities:

Completed preclinical requirements.

Completed phase I.

Completed phase IIa.

Initiated FDA discussions.

Completed phase IIb.

Entered into a deal with US company.






Lupuzor™ : Phase IIb results

All inclusive un-adjusted ITT analysis

Difference over placebo


147 patients



Target Population, Clinical SLEDAI score >6

Difference over placebo

134 patients



3 months administration in addition to steroids or other “standard care” treatment.

The primary efficacy endpoint was based on the “combined score”.

Graphs are plotted using placebo figures as a base of 100.

Cephalon Deal

- Deal size up to \$500m milestones + high tiered royalties.
- Cephalon paid IMM \$45m.
- Cephalon assumed all responsibilities and costs for development and commercialisation worldwide.
- Cephalon acquired by Teva Oct 2011.
- ImmuPharma regained rights due to acquisition.





Lupuzor™ : Highlights of Development Status

The “End of Phase 2” meeting package was submitted to the US FDA and the FDA responded in writing to all the questions.

The IMPD (Investigational Medicinal Product Dossier) submitted via the Voluntary Harmonized Procedure (VHP) in the EU was approved.

The Scientific Advice meeting with the European Medicines Evaluation Agency (EMA) was held; the recommendations were very similar to those in the FDA’s “End Of Phase 2” responses. Recommendations were incorporated into the Phase 3 pivotal studies’ design.

The Japanese PMDA meeting request was submitted.



Lupuzor™ : Highlights of Development Status

FDA granted approval to start phase III based on ImmuPharma phase IIb data, with an SPA.

FDA granted Lupuzor™ Fast Track designation.

Japanese “FDA” (PMDA) approved start of clinical trials in Japan.

Active ingredient (API) for phase III commercial validation batches have been produced by Cephalon and is now ImmuPharma’s.





Lupuzor™ Tech Transfer in process

Cephalon agreed to transfer everything to ImmuPharma

ImmuPharma has put in place the necessary sub-contractors for the Tech Transfer; expected to be complete in a matter of weeks

ImmuPharma has no payment obligations to Cephalon





IPP-204106

Treatment of Cancer

Potential breakthrough cancer drug just finalising phase Ib/IIa clinical trials in cancer patients.

Dual mechanism: reduces proliferation as well as angiogenesis.

Novel target: nucleolin/nucleophosmin.

Major funding grant received from prestigious French state organisation.



IPP-204106

Development Update

Received approval from French regulatory authorities (AFSSAPS), for a Phase I/IIa study in cancer patients.

Commenced dose escalating open label study in cancer patients with progressive disease and at least one treatment failure with another cancer treatment.

The study was designed to show safety and tolerability and assess the maximum tolerated dose and took place in two hospitals in Paris and one in Dijon.

The patients dosed were suffering from different types of cancer including breast cancer, lung cancer or bladder cancer and all had metastasis.

No serious drug-related adverse events have so far been reported. Some patients have been rated as being “stabilised”.



IPP-204106

Compound Highlights

Publication was chosen to be the cover article of the May 2011 issue of the prestigious Cancer Research medical journal in the US.

Phase Ib/IIa trial: good safety profile (endpoint).

One patient surviving after 16 months of treatment.

Another patient surviving after 8 months of treatment.

Interim report in drafting.



IPP-102199

Treatment of Pain

Cancer pain & post-surgical pain.
Potential replacement for
morphine and other opioids.
May provide longer pain relief
with limited side effects.
Large US market size \$5bn
(Datamonitor).






IPP-203101

Treatment of MRSA

MRSA and severe hospital
acquired infections.

Hospital use.

May not be limited by bacterial
resistance due to its biophysical
mechanism of action



Promising in-vitro efficacy results:

- Minimum Inhibitory Concentration (MIC) similar to Vancomycin
- Activity also against *E. coli* and *P. aeruginosa*



IPP-201007


Inflammation

Selective phospholipase A2 subtype inhibitors discovered from ImmuPharma's library. New molecules with potential application in inflammatory/allergic conditions such as asthma and rheumatoid arthritis.





Long-Term Pipeline






ImmuPharma

Peptide to Drug Converting Technology (underlying IPP-102199 for pain)

Could be applied to other peptides
(IPP-102199's peptide = met
enkephalin); increases peptide's half-
life and efficacy.

May turn small physiologically active
peptides into commercially viable
molecules.






Proprietary Library

Over 300,000 patented small molecules.

70% Drug-like (most commercial libraries: 35%).

Validated through the discovery of IPP-201007




Summary

Lupuzor™ - FDA approval granted to start phase III with an SPA plus Fast Track designation. ImmuPharma regained rights to a highly valuable asset. Corporate deal discussions initiated.

Cancer compound: Second potential blockbuster in clinical trials in cancer patients.

Promising pipeline and continual support from the CNRS.

Strong balance sheet.





ImmuPharma plc
50 Broadway
Westminster
London SW1H 0RG
U.K.

Tel: +44 20 7152 4080
Fax: +44 20 7152 4001

www.immupharma.com

UK Advisers

Nominated Advisor & Broker

Panmure Gordon

Joint Broker

Espirito Santo Investment Bank

Analysts

Merchant Securities

Panmure Gordon

Espirito Santo Investment Bank (Execution Noble Group)

Edison Investment Research

Public Relations & Investor Relations

Buchanan Communications

Broker Profile

Auditors

Nexia Audit Limited

Solicitors

Bircham Dyson Bell